

MULTISHIELD DC

Intramammary Suspension for Cows

DATA
SHEET



INDICATIONS

Treatment of subclinical mastitis in cows at drying off caused by microorganisms susceptible to the combination of penicillin and neomycin; and as part of strategy for the prevention of new infections occurring during the dry period.

BENEFITS

Broad spectrum activity.

Each 4.5g intramammary syringe contains;

- Neomycin Sulphate 100mg
- Penethamate Hydriodide 100mg
- Procaine Benzylpenicillin 400mg



LIST No	UNIT PACKAGE	CASE SIZE
1MUL024	4.5g Syringe	120

See reverse for Administration & Dosage



MULTISHIELD DC

Intramammary Suspension for Cows



PRESENTATION

A smooth, off white, oily intramammary suspension. Each 4.5g intramammary syringe contains the active substances:

Neomycin 70 000 IU (corresponding to Neomycin Sulphate 100 mg)
Penethamate 77.2 mg (corresponding to Penethamate Hydriodide 100 mg)
Benzylpenicillin 227.2 mg (corresponding to Procaine Benzylpenicillin 400 mg)

TARGET SPECIES

Cows (at dry off)

INDICATIONS FOR USE

In cows at drying off: Treatment of subclinical mastitis caused by microorganisms susceptible to the combination of active substances penicillin and neomycin, and as part of strategy for the prevention of new infections occurring during the dry period.

CONTRAINDICATIONS

Do not use in lactating cows.

Do not use in cases of hypersensitivity to β -lactam antibiotics, cephalosporin antibiotics, neomycin or other aminoglycoside antibiotics or to any of the excipients.

Do not use in cows with clinical mastitis.

SPECIAL PRECAUTIONS FOR USE IN ANIMALS

Use of the product should be based on susceptibility testing. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Official, national and regional antimicrobial policies should be taken into account when the product is used. The therapeutic efficacy of the product is only established against pathogens that are susceptible to the active substances.

Serious acute mastitis [potentially lethal] due to pathogens like *Pseudomonas aeruginosa*, can occur after drying off despite preventive treatment. Good aseptic practices should be thoroughly respected in order to reduce that risk; cows should be housed in a hygienic paddock and regularly checked several days after drying off.

Use of the product deviating from the instructions given may increase the prevalence of bacteria resistant to benzylpenicillin and may decrease the effectiveness of treatment with other beta-lactam antimicrobials (penicillins and cephalosporins) due to the potential for cross-resistance.

SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE PRODUCT

Avoid contact with this preparation as occasionally skin allergy may occur.

May cause sensitisation following injection, inhalation, ingestion or skin contact. Sensitivity to penicillins may lead to cross sensitivity to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Do not handle this product if you know that you are sensitised or if you have been advised not to work with such preparations.

If you develop symptoms such as a skin rash following exposure, seek medical advice and show this warning to the doctor. Swelling of the face, lips or eyes, or difficulty with breathing are more serious symptoms and require urgent medical attention.

ADVERSE REACTIONS

Allergic reactions (allergic skin reactions, anaphylaxis) Penicillins may cause hypersensitivity following administration. Allergic reactions to these substances may occasionally be serious.

The frequency of adverse reactions is very rare. (More than 1 but less than 10 animals in 10,000 animals treated)

If adverse reactions occur, the current treatment should be withdrawn and symptomatic treatment should be initiated.

USE DURING PREGNANCY AND LACTATION

The product is not recommended for use in lactating cows, except at the drying off stage.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONS

No data available

AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE

Single intramammary administration. The contents of one syringe should be infused into each quarter via the teat canal immediately after the final milking of a lactation. i.e. 100 mg of neomycin sulphate, 100 mg of penethamate hydriodide and 400 mg of procaine benzylpenicillin into each quarter.

Before instillation, the udder should be milked out completely. The teat and its orifice should be thoroughly cleaned and disinfected. Care should be taken to avoid contamination of the injector nozzle. Gently insert the contents of one syringe into each quarter. Disperse the product by gentle massage of the teat and udder. The syringe must only be used once.

OVERDOSE

Invalidates the stated milk and meat withdrawal times.

WITHDRAWAL PERIODS

Meat and Offal: 28 days

Milk: 96 hours post calving in cows with a dry period of more than 50 days.

50 days plus 96 hours after treatment from cows with a dry period of 50 days or less.

PHARMACODYNAMIC PROPERTIES

Contains an aminoglycoside (neomycin sulphate) and two penicillin derivatives (procaine benzyl penicillin and penethamate hydriodide).

Aminoglycosides disturb the permeability of the bacterial cell membrane by an effect exerted during cell wall development. Once the aminoglycoside has entered the cell, it binds to the target site on the ribosome, inducing misreading of the genetic code. Neomycin in common with other aminoglycosides has activity predominantly against gram negative microorganisms. Neomycin has been shown to have synergistic activity with β -lactam antibiotics against Gram positive bacteria.

Penicillins have a time-dependent, bacteriocidal effect by interfering with microbial cell wall synthesis. They inhibit the activity of transpeptidase enzymes which catalyse cross linkage of the glycopeptide polymer units that form the cell wall. Both procaine benzylpenicillin and penethamate hydriodide are hydrolysed in the udder to release free penicillin.

Bovine mastitis microorganisms which can be treated with the product include susceptible isolates of *Staphylococcus aureus*, *Streptococcus agalactiae*,

Streptococcus uberis, other susceptible *Streptococcus* spp., *Trueperella pyogenes* and susceptible isolates of *E.coli*.

The predominant mechanism of penicillin resistance in Gram-negative bacteria is the production of β -lactamase enzymes and this is also a well-recognised feature of some *Staphylococcus* spp. isolates. Alteration of the penicillin binding proteins is a less prevalent resistance mechanism however this has been recorded in some bovine mastitis isolates of *Staphylococcus* spp. Reported penicillin resistance levels vary considerably between geographical areas. The prevalence of resistance against neomycin remains low in those species.

Enzymatic modification is the most common type of aminoglycoside resistance. There are only limited reports of identification of the genes for enzymes active against neomycin in veterinary mastitis pathogens.

PHARMACOKINETIC PARTICULARS

Penethamate hydriodide is an ester of benzylpenicillin which is rapidly hydrolysed at pH 7.3 to liberate free penicillin which quickly distributes throughout the udder tissue.

Procaine benzylpenicillin is a complex, sparingly soluble organic salt of benzylpenicillin and its use, in combination with a slow-release base, is intended to delay release of the active penicillin moiety at the site of administration and so give rise to a prolonged duration of action.

Neomycin is a poorly lipid soluble, basic aminoglycoside that shows a high degree of binding to udder tissue and has low systemic absorption thus it persists in the udder for a prolonged period after administration.

EXCIPIENTS

Liquid paraffin, Aluminium di/tristearate.

SHELF LIFE

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.

Syringes are for single use only.

STORAGE

Do not store above 25°C.

Do not refrigerate or freeze.

DISPOSAL

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

LEGAL CATEGORY

POM-V

MARKETING AUTHORISATION NUMBER

Vm 50146/4005

MARKETED IN THE UK BY

Bimeda UK

Unit 2, Bryn Cefni Industrial Park
Llangefni, Anglesey,
Wales, LL77 7XA
01248 725400

Use Medicines Responsibly.

Noah.co.uk/responsible

TAKE TIME



OBSERVE LABEL
DIRECTIONS

www.bimeda.co.uk

Bimeda data sheet created: January 2021

Global Excellence in Animal Health

 **Bimeda**